James Field (@jejfield) 's Twitter Profile
James Field

@jejfield

AI driven evolution - CEO & Founder at @LabGeni_us / @BBSRC Innovator of the Year / @Forbes 30 under 30 / occasional Angel investor / Dad

ID: 3005376135

linkhttps://labgeniustx.com/ calendar_today30-01-2015 11:40:55

334 Tweet

1,1K Takipçi

1,1K Takip Edilen

Chris Gibson (@recursionchris) 's Twitter Profile Photo

London TechBio community coming together in KX tonight hosted by ⁦Recursion⁩ and ⁦⁦Valence Labs⁩ ! Super excited to join up with so many incredible academics, startups, large tech companies, large bio companies and investors. Future feels very bright!

London TechBio community coming together in KX tonight hosted by ⁦<a href="/RecursionPharma/">Recursion</a>⁩ and ⁦⁦<a href="/valence_ai/">Valence Labs</a>⁩ ! Super excited to join up with so many incredible academics, startups, large tech companies, large bio companies and investors. Future feels very bright!
Recursion (@recursionpharma) 's Twitter Profile Photo

Earlier today, we hosted a mixer to celebrate our #London office announcement with some key members and brightest minds in the #techbio ecosystem. Thanks to our amazing panelists Laksh James Field, Julia Fan Li Dan & Chris Gibson.

Earlier today, we hosted a mixer to celebrate our #London office announcement with some key members and brightest minds in the  #techbio ecosystem. 
Thanks to our amazing panelists <a href="/LakshAithani/">Laksh</a>  <a href="/jejfield/">James Field</a>, <a href="/juliafanli/">Julia Fan Li</a> <a href="/_danielcohen/">Dan</a> &amp; <a href="/RecursionChris/">Chris Gibson</a>.
LabGenius Therapeutics (@labgeni_us) 's Twitter Profile Photo

Attending OBN_UK #BioTrinity 2024? Be sure to catch James Field, James Field CEO & Founder, who will be presenting as part of the 'Oncology R&D Spotlight' session on Wednesday, April 24th, from 09:30 to 10:45. And if you'd like to meet with James to learn about our ML-driven

Attending <a href="/OBN_UK/">OBN_UK</a> #BioTrinity 2024? 

Be sure to catch James Field, <a href="/jejfield/">James Field</a> CEO &amp; Founder, who will be presenting as part of the 'Oncology R&amp;D Spotlight' session on Wednesday, April 24th, from 09:30 to 10:45. 

And if you'd like to meet with James to learn about our ML-driven
LabGenius Therapeutics (@labgeni_us) 's Twitter Profile Photo

We're looking forward to connecting with prospective partners at #LSXWorldCongress in London April 29-30. Meet with James Field, CEO & Founder James Field, and Tonya Frolov (BD) to explore the discovery of next generation therapeutic antibodies across a range of application areas.

We're looking forward to connecting with prospective partners at #LSXWorldCongress in London April 29-30. Meet with James Field, CEO &amp; Founder <a href="/jejfield/">James Field</a>,  and Tonya Frolov (BD) to explore the discovery of next generation therapeutic antibodies across a range of application areas.
James Field (@jejfield) 's Twitter Profile Photo

Thanks for visiting LabGenius Therapeutics HQ today Brad Loncar ! Really enjoyed talking about our work combining high throughput experimentation with ML to engineer novel multispecific antibodies. 🧬🤖

James Field (@jejfield) 's Twitter Profile Photo

Exclusive behind-the-scenes footage from LabGenius Therapeutics The Movie 📽️ with my good friend and mentor MC HAMMER e/acc. 👊 To all founders working hard to build a better future, don't forget to have a little fun along the way. This is your journey!

LabGenius Therapeutics (@labgeni_us) 's Twitter Profile Photo

EXCITING NEWS! 📣 Today we announce LabGenius’ £35 million Series B fundraise! 🎉🚀 With these funds, we’ll be accelerating the development of both our ML-driven drug discovery platform and therapeutic pipeline of multispecific antibodies 🔬 🗞️ For more details on the round,

James Wise (@jamespaulwise) 's Twitter Profile Photo

Following the news of their £35M funding round, I sat down with James Field, CEO and founder of LabGenius Therapeutics for the latest episode of What's Next. LabGenius is on a mission to not only find novel therapeutics, but to use AI to augment the scientific method itself. In this

Bloomberg UK (@bloomberguk) 's Twitter Profile Photo

LabGenius is harnessing the power of AI and machine learning to accelerate the discovery new medicines They're one of Bloomberg's 25 UK startups to watch for 2024 bloom.bg/3Yc417L

LabGenius Therapeutics (@labgeni_us) 's Twitter Profile Photo

Are you attending #PEGSEurope? Join our CEO, James Field, as he describes how LabGenius’ unique discovery platform is being used to establish a wholly-owned pipeline of highly selective T-cell engagers for the treatment of solid tumours. LabGenius’ platform, which is underpinned

Are you attending #PEGSEurope?

Join our CEO, James Field, as he describes how LabGenius’ unique discovery platform is being used to establish a wholly-owned pipeline of highly selective T-cell engagers for the treatment of solid tumours. LabGenius’ platform, which is underpinned
Phytoform (@phytoformlabs) 's Twitter Profile Photo

Phytoform’s tiny, tasty tomatoes are packing a punch within vertical farms. If you want to learn more about how Phytoform are revolutionising the industry with precision breeding see below #precisionbreedingcrops agfundernews.com/phytoform-says…

LabGenius Therapeutics (@labgeni_us) 's Twitter Profile Photo

Attending BioTrinity (OBN_UK) next week? Join LabGenius Therapeutics' CEO, James Field, for his Science Spotlight presentation describing how our unique discovery platform is being used to establish a wholly-owned pipeline of highly selective T-cell engagers for the treatment of solid

Attending BioTrinity (<a href="/OBN_UK/">OBN_UK</a>) next week?

Join <a href="/labgeni_us/">LabGenius Therapeutics</a>' CEO, James Field, for his Science Spotlight presentation describing how our unique discovery platform is being used to establish a wholly-owned pipeline of highly selective T-cell engagers for the treatment of solid
LabGenius Therapeutics (@labgeni_us) 's Twitter Profile Photo

LabGenius’ CSO, Gino Van Heeke, recently wrote an article for BioSpace, exploring how the next generation of ‘smart’ antibodies will transform the fight against solid tumours. The piece delves into a critical challenge: overcoming on-target, off-tumour toxicity—a key obstacle

LabGenius’ CSO, Gino Van Heeke, recently wrote an article for <a href="/biospace/">BioSpace</a>, exploring how the next generation of ‘smart’ antibodies will transform the fight against solid tumours.

The piece delves into a critical challenge: overcoming on-target, off-tumour toxicity—a key obstacle
Qualio (@qualiohq) 's Twitter Profile Photo

Super antibodies that target 400x more effectively? 🎯 For James Field, CEO of LabGenius Therapeutics, the combination of human and artificial intelligence holds the key to dramatically powerful new treatments. Catch him on our podcast 👇 hubs.ly/Q03lckjh0 #ai #lifescience